RESUMO
The evolution of treatment of chronic hepatitis C virus infection has led to improved therapeutic efficacy. However, a major problem is the presence of side effects that require modification or withdrawal of drug therapy in 15-20% of cases. This could potentially influence the lack of sustained viral response in 50% of the cases. Side effects are common, even with pegylated interferon. This study aimed to assess the incidence and severity of infections based on the development of neutropenia associated with combined therapy with pegylated interferon-alpha2a plus ribavirin in 209 patients with chronic hepatitis C infection. All patients were administered pegylated interferon-alpha2a (180 microg/week) plus ribavirin (800 mg/day for 24 weeks in cases of nongenotype 1, or 1000-1200 mg/day for 48 weeks for genotype 1, according to whether patients weighed more or less than 75 kg). Patients with preexisting neutropenia of any cause or cirrhosis were excluded. Neutropenia was defined as a neutrophil count (NC) of <1500 cells/microl. Neutropenia was classified into three levels during treatment: 750Assuntos
Antivirais/efeitos adversos
, Hepatite C Crônica/complicações
, Interferon-alfa/efeitos adversos
, Neutropenia/induzido quimicamente
, Ribavirina/efeitos adversos
, Adulto
, Idoso
, Antivirais/uso terapêutico
, Quimioterapia Combinada
, Feminino
, Hepatite C Crônica/tratamento farmacológico
, Humanos
, Interferon alfa-2
, Interferon-alfa/uso terapêutico
, Contagem de Leucócitos
, Modelos Logísticos
, Masculino
, Pessoa de Meia-Idade
, Neutropenia/patologia
, Polietilenoglicóis
, Proteínas Recombinantes
, Ribavirina/uso terapêutico